Incidence and Risk Factors for Cholangiocarcinoma in Primary Sclerosing Cholangitis

  title={Incidence and Risk Factors for Cholangiocarcinoma in Primary Sclerosing Cholangitis},
  author={Kelly W. Burak and Paul Angulo and Tousif M. Pasha and Kathleen S. Egan and Janice L. Petz and Keith D. Lindor},
  journal={American Journal of Gastroenterology},
Cholangiocarcinoma (CCA) is a dreaded complication of primary sclerosing cholangitis (PSC); however, marked variability in the incidence of CCA in PSC is reported. Furthermore, limited information exists on risk factors for the development of CCA in PSC. The aim of this study was to determine the incidence of CCA in patients with PSC and to evaluate baseline risk factors for the later development of CCA. From a previous study of the natural history of PSC, we identified 161 patients with PSC… 

Tables from this paper

Advances in the diagnosis of cholangiocarcinoma in patients with primary sclerosing cholangitis

  • L. E. Moreno LunaG. Gores
  • Medicine
    Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society
  • 2006
Primary sclerosing cholangitis (PSC) is an idiopathic chronic cholestatic liver disease characterized by inflammatory destruction of the biliary tree. It slowly progresses, resulting in biliary

Cholangiocarcinoma in Patients with Primary Sclerosing Cholangitis (PSC): a Comprehensive Review

More attention should be paid to PSC patients presenting with an abrupt aggravation of jaundice, pain, fatigue, pruritus, weight loss, or worsening liver biochemistries, in particular within the first year after PSC diagnosis.

Dissecting the genetic susceptibility for cholangiocarcinoma in primary sclerosing cholangitis

Primary sclerosing cholangitis (PSC) is an idiopathic cholestatic liver disease caused by fibrosing inflammation of the bile ducts and represents an established risk factor for development of

Review of incidence and outcomes of treatment of cholangiocarcinoma in patients with primary sclerosing cholangitis

Insight is provided about particular features of CCA in the setting of PSC, with a main focus on its incidence, considerations relating to its anatomical location and implications to treatment and outcomes, through the viewpoint of historical evolution of management, and future perspectives.

Screening for Malignancy in Primary Sclerosing Cholangitis (PSC)

Although AASLD guidelines do not recommend routine screening for liver tumors in patients with PSC, it is recommended that MRI/MRCP and serum CA 19-9 levels are recommended every 6 months to screen for CCA, HCC, pancreatic cancer, and gallbladder cancer.

Cholangiocarcinoma in patients with primary sclerosing cholangitis.

Despite ongoing advancements in the study of PSC-associated CCA, early diagnosis of CCA remains difficult, treatment options are limited, and prognosis is often consequently poor; Continued research in the development of high-accuracy diagnostic tools, novel biomarkers, and surveillance techniques may help to increase the likelihood of diagnosing CCA at earlier stages.

Diagnosis of cholangiocarcinoma in patients with PSC: a sight on cytology.

Cholangiocarcinoma in Young Individuals With and Without Primary Sclerosing Cholangitis

The youth group of cholangiocarcinoma plus PSC seems to have a higher prevalence of Crohn's disease whereas the prognosis in youth seems to be similarly poor as described in older patients with cholangsiocARCinoma.

Cholangiocarcinoma: risk factors and clinical presentation.

  • M. GattoD. Alvaro
  • Medicine
    European review for medical and pharmacological sciences
  • 2010
A number of serum and bile biomarkers have been recently proposed for the diagnosis of CCA but, their impact on the early diagnosis is still under the evaluation.

Primary sclerosing cholangitis-associated cholangiocarcinoma: special considerations and best practices

This review discusses important considerations in the clinical epidemiology, risk factors, diagnosis, and surveillance of PSC-associated CCA, and the recent introduction of recommendations for CCA surveillance will likely improve outcomes.



Cholangiocarcinoma in patients with primary sclerosing cholangitis: A multicenter case‐control study

It is concluded that alcohol consumption was a risk factor for having CCA in PSC patients and serum CA 19‐9 appeared to have good ability to discriminate P SC patients with and without CCA.

Survival and risk of cholangiocarcinoma in patients with primary sclerosing cholangitis. A population-based study.

Patients with PSC have a substantially decreased survival, which is most pronounced among patients without IBD, and the risk of cholangiocarcinoma is highest among patients with a diagnosis of inflammatory bowel disease.

Biliary malignancies in primary sclerosing cholangitis: Timing for liver transplantation

Early timing of transplantation in patients with PSC is suggested to prevent formation of biliary malignancies, and regular scoring of patients with the Mayo Model risk score should be taken into consideration at scores above 4.4.

Risk factors and clinical presentation of hepatobiliary carcinoma in patients with primary sclerosing cholangitis: A case‐control study

Clinical and biochemical presentation of PSC patients with and without hepatobiliary carcinoma did not differ during the year before cancer diagnosis/Ltx, and smoking seems to be a risk factor for developing hepatobility carcinoma in patients with PSC.

Natural history and prognostic factors in 305 Swedish patients with primary sclerosing cholangitis.

It was found that age, serum bilirubin concentration, and histological stage at the time of diagnosis were independent predictors of a bad prognosis, which should be of value for the timing of transplantation and patient counselling in PSC.

CA 19-9 and CEA are unreliable markers for cholangiocarcinoma in patients with primary sclerosing cholangitis.

Tumor markers as a diagnostic tool in diagnosing cholangiocarcinoma in patients with PSC are unfortunately not as valuable as previously reported.

Predicting cholangiocarcinoma in patients with primary sclerosing cholangitis: An analysis of the serological marker CA 19‐9

The measurement of serum concentrations of CA 19‐9 is a promising test for detecting cholangiocarcinoma in patients with PSC.